Presentation title: Neoadjuvant biomarker trial of pepinemab to enhance nivolumab or ipilimumab activity in resectable head and neck cancer. Abstract 103. Time: 9:45-11:15 AM CST/10:45 AM – 12:15 PM ...

MOUNTAIN VIEW, CA / ACCESS Newswire / May 13, 2025 / AbTherx, Inc., a biotechnology company with innovative transgenic technologies that simplify and accelerate antibody discovery, today announced a ...

Neoadjuvant treatment with pepinemab appears to induce abundant, mature lymphoid structures that correlate with durable clinical benefit of immunotherapy in patients with metastatic melanoma.

Neoadjuvant treatment with pepinemab appears to induce abundant, mature lymphoid structures that correlate with durable clinical benefit of immunotherapy in patients with metastatic melanoma.

Vaccinex, Inc., a clinical-stage biotechnology company focused on treating neurodegenerative diseases, has announced that it will be delisted from the Nasdaq Stock Market due to its failure to meet ...

ROCHESTER, N.Y., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to treating ...

Vaccinex, Inc. (NASDAQ:VCNX) shares are trading lower after the company announced it received a delisting notification from the Nasdaq. Here’s what you need to know. What To Know: Vaccinex disclosed ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...

ROCHESTER, N.Y., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Vaccinex (VCNX), Inc. , a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease ...

Vaccinex (VCNX) announced the signing of several proprietary project agreements with Amgen, Merck, Chugai, Absci, Gigagen, Merus, Soleil, ThirdArc and Incyte, employing Vaccinex’s ActivMAb technology ...